Pronota announces EUR 3.7 mil­lion Series C financ­ing; man­age­ment and board changes

Ghent, Belgium, 20th January 2012 – Pronota NV today announced the close of a Series C financ­ing, rais­ing EUR 3.7 mil­lion from exist­ing investors; LSP, Gimv, Biotech Fund Flanders, KBC Private Equity, Johnson & Johnson Development Corporation, VIB, MP Healthcare and MedSciences Capital, and a com­pa­ny founder.
The pro­ceeds will be used to com­plete the pro­tein bio­mark­er val­i­da­tion stud­ies for Pronota’s inno­v­a­tive diag­nos­tic prod­ucts in its preeclamp­sia, ovar­i­an can­cer, sep­sis and car­dio-renal pro­grams.
In addi­tion, Pronota announced that Nick McCooke is step­ping down as CEO and board mem­ber to pur­sue oppor­tu­ni­ties clos­er to his home base in the UK after near­ly 6 years as CEO. He is being replaced by Katleen Verleysen, pre­vi­ous­ly COO. At the same time, John Berriman is step­ping down as chair­man to be replaced by Rudy Dekeyser, man­ag­ing direc­tor of VIB.
Incoming CEO Katleen Verleysen com­ment­ed: “I wel­come and draw great con­fi­dence from our investors’ con­tin­ued sup­port as we push our prod­ucts for­ward to com­plete clin­i­cal proof of con­cept, build­ing on the excit­ing results of the first stages of clin­i­cal val­i­da­tion. I’d also like to take the oppor­tu­ni­ty to express the Board’s thanks to both Nick and John mak­ing Pronota the leader in tak­ing nov­el pro­tein bio­mark­ers from dis­cov­ery through to clin­i­cal appli­ca­tion. I’m excit­ed to be work­ing on the next stage of the jour­ney as we fur­ther build the val­ue of our prod­ucts, which are already attract­ing strong inter­est from diag­nos­tic com­pa­nies.”

Leave a Reply

Your email address will not be published. Required fields are marked *